Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Subcutaneous MK-3475A Versus Intravenous Pembrolizumab in First-line Metastatic NSCLC With PD-L1 TPS ≥50%
2024-513165-39-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve (AUC) of Pembrolizumab After First Dose and Trough Concentration (Ctrough) of Pembrolizumab at Steady State. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513165-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513165-39-00.